Top South Korean Official in US Again as Tariff Deadline Looms
Wi Sung-lac departed for the US 'to engage in various negotiations with US officials,' Woo Sang-ho, a senior presidential secretary, told reporters Sunday. 'This may not be the last time, and it could continue,' Woo said, adding that the top security official 'will visit the US whenever he deems it necessary for the overall negotiations.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
'Like they're set in their ways': Some Indigenous leaders not happy with projects as premiers meet
Canada's premiers are gathering in Huntsville, Ont., on Monday ahead of a meeting with Prime Minister Mark Carney. Once again the economy and U.S. President Donald Trump's tariffs are at the top of the agenda, with more levies against Canadian goods expected in the coming weeks. As Mackenzie Gray reports, there are still differing opinions on how best to tackle the problem.
Yahoo
23 minutes ago
- Yahoo
In South Korea's 'apple county', farmers beg not to be sacrificed for US trade deal
By Hyunjoo Jin CHEONGSONG, South Korea (Reuters) -The apples grown in the South Korean county of Cheongsong in the country's southeast are so renowned for their flavour that they are often given out in neatly-packaged gift boxes during national holidays. But apple farmers, who account for about a third of the roughly 14,000 households in the sleepy rural area, worry that their way of life could be under threat from an influx of cheap U.S. imports. Fanning concerns, South Korea's trade minister suggested last week that Seoul could make concessions on some agricultural imports, although he said sensitive items should be protected, as part of any deal to eliminate or reduce punishing U.S. tariffs on cars, steel and other key exports. "U.S. apples are very cheap. We can't compete with them," said Shim Chun-taek, a third-generation farmer who has been growing apples for two decades. He now fears South Korean farmers risk being sacrificed to appease the U.S. and support the country's manufacturing sector. The United States has long called for better market access for its farm products from beef to apples and potatoes. U.S. President Donald Trump in April slammed steep tariffs on rice in South Korea and Japan. South Korea has taken steps to open its market and is now the top buyer of U.S. beef and the sixth-biggest destination for U.S. agricultural exports overall. Still, Washington has complained about persistent non-tariff barriers. South Korea's quarantine agency is still reviewing U.S. market access requests for apples more than 30 years after they were filed, sparking calls by Washington to expedite the approval process for a range of fruits and potatoes. SURGING PRICES Any opening up of the sector would increase pressure on apple farmers already wrestling with a host of problems, from climate change to an ageing population and wildfires, which have led to rising costs, smaller harvests, and higher prices. Bank of Korea governor Rhee Chang-yong last year said runaway prices of apples and other farm goods were contributing to inflation and that there was a need to consider more imports. The central bank noted South Korea's grocery prices were higher than the average for OECD countries, with apple prices nearly three times higher than the OECD average. "I think it is difficult to justify absolute protection to certain agriculture sectors simply because of its high sensitivity," said Choi Seok-young, a former chief negotiator for the Korea-U.S. free trade deal. It was hard to view the delayed quarantine process as "rational based on science and international norms," added Choi, who is now a senior adviser for law firm Lee & Ko. Agriculture has emerged as one of the sticking points in U.S. trade talks with South Korea and Japan, after countries such as Indonesia and Britain agreed to allow more agricultural imports from the U.S. in recent trade deals. Seoul has long restricted shipments of U.S. beef from cattle older than 30 months. Massive protests from South Koreans worried about safety due to mad cow disease followed a 2008 agreement with the United States to lift the restrictions. Shim, 48, who wakes at 3 a.m. every morning to work on his orchards, said it would be impossible to find alternative crops to grow in the mountainous area. The tariff talks have already fuelled protests from farmers' groups. There could be more to come. "We oppose the imports of apples no matter what," Youn Kyung-hee, mayor of Cheongsong county, told Reuters, adding that people will not "sit still" if Seoul opens up the market. ($1 = 1,391.1000 won) Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) with an EGFR exon 19 deletion or L858R mutation with disease progression on or after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy. DB-1310 is a novel ADC targeting HER3 developed using DualityBio's proprietary DITAC platform. In June 2025, Dr. Aaron E. Lisberg from the University of California, Los Angeles (UCLA) presented the first-in-human Phase I/IIa clinical trial data (NCT05785741) of DB-1310 in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The results demonstrated encouraging efficacy and a manageable safety profile in patients with advanced solid tumors who had failed standard therapies. Dr. Hua Mu, Global Chief Medical Officer of DualityBio, stated: "DB-1310 demonstrated encouraging clinical efficacy and manageable safety in patients with EGFRm nsqNSCLC and multiple solid tumors. It is noteworthy that preclinical investigations of DB-1310 in combination with EGFR TKIs and other anticancer agents have also demonstrated robust synergistic tumor suppression activity. We will spare no effort to accelerate the clinical development of DB-1310 and look forward to its potential, as a next-generation HER3 ADC, to become a novel therapeutic option for a broad population of cancer patients." About DualityBio Duality Biotherapeutics is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune diseases. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, DualityBio is conducting multiple global clinical trials across 17 countries, has enrolled over 2,000 patients for multiple clinical-stage ADC candidates. Additionally, DualityBio have established strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing bispecific ADCs, novel-payload ADCs, and autoimmune ADCs. For more information, please visit View original content to download multimedia: SOURCE Duality Biotherapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
